What Is Disease Modifying Therapy? Evidence-Based Disease Modification in Multiple Sclerosis

RELEASE DATE: December 30, 2020


Provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.

This activity is supported by an independent education grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.0 contact hours of continuing nursing education
  • Pharmacists — maximum of 1.0 contact hours of continuing pharmacy education

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of neurologists, nurses, nurse practitioners, PAs, pharmacists, and other members of the healthcare team essential to optimal management of patients with MS.

Program Overview

This interactive activity incorporates polling questions about common decision-making dilemmas in the treatment of multiple sclerosis (MS) with disease-modifying therapy. Following each polling question, our expert faculty will review relevant evidence and share examples of patient cases that illustrate considerations for starting, switching, and discontinuing therapy.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review evidence-based principles for setting treatment goals and starting disease-modifying therapy in patients diagnosed with MS
  • Employ approaches to evaluating treatment response and switching therapies when needed
  • Review considerations for stopping treatment in patients living with MS
  • Describe the effective team-based strategies that promote optimal patient outcomes


Joseph R. Berger, MD, FACP, FAAN, FANA
Professor of Neurology and Associate Chief of the MS Division
Perelman School of Medicine
University of Pennsylvania

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation
The CMSC designates this activity for a maximum of 1.0 contact hours of continuing nursing education (1.0 in the area of pharmacology).

This knowledge-based activity, UAN JA4008165-9999-20-071-H01-P, qualifies for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit.

Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. Paper certificates are not valid. For information about CPE Monitor, visit

Instructions for Participation and Credit

This activity is an online enduring material. There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, completing the pre-test, viewing the video, studying the educational activity and completing the post-test and the evaluation form. Upon completion of the evaluation, your certificate will be made available immediately. Click on “View Certificate” and print the certificate for your records.

The estimated time to complete the activity is 60 minutes.

This activity was originally released on December 30, 2020 and is eligible for credit through December 30, 2021.

Contact Information

For questions about this activity, please contact Catamount Medical Education at [email protected].